← Procept Biorobotics overview

Procept Biorobotics vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Procept Biorobotics Corp (PRCT)

Q3 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

July 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

Latest
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

Baxter International Inc (BAX)

Q3 2026
▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

  • Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.

    This is the main new event that moved BAX and reset expectations for the year.

  • Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.

    It is a new capital-structure action that affects how investors view BAX's debt load.

  • Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.

    It is the main negative in the new results and explains why the beat is not purely good news.

  • Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.

    It is a specific new operational risk flagged alongside the raised outlook.

August 2026
▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

  • Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.

    This is the main new event that moved BAX and reset expectations for the year.

  • Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.

    It is a new capital-structure action that affects how investors view BAX's debt load.

  • Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.

    It is the main negative in the new results and explains why the beat is not purely good news.

  • Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.

    It is a specific new operational risk flagged alongside the raised outlook.

Latest
▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

  • Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.

    This is the main new event that moved BAX and reset expectations for the year.

  • Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.

    It is a new capital-structure action that affects how investors view BAX's debt load.

  • Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.

    It is the main negative in the new results and explains why the beat is not purely good news.

  • Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.

    It is a specific new operational risk flagged alongside the raised outlook.